Company: NCEL
Filing Date: 2025-09-03
Form Type: F-4/A
Source: 0001213900-25-084157
Chunk: 58

Company: NewcelX Ltd.
Filing Date: 2025-09-03
Form: F-4/A
Chunk 58
---
 wholly -ownedsubsidiary of NLS and (ii) each issued and outstanding ordinary share of Kadimastem, no par value, or Kadimastem Ordinary Share, immediately prior to the consummation of the merger will no longer be outstanding and will automatically be cancelled, in exchange for the right of the holder thereof to receive a substantially equivalent security of NLS, or the Merger. NLS is providing these proxy materials in connection with the solicitation by the NLS Board of proxies to be voted at a meeting of our shareholders to be held on September 29, 2025, commencing at 4:00 pm, local time, at the premises of Baker McKenzie Switzerland AG, Holbeinstrasse30, 8034 Zurich, Switzerland, or at any adjournment or postponement thereof. This proxy statement/prospectus and the enclosed proxy card will be mailed to each shareholder entitled to notice of, and to vote at, the NLS Meeting commencing on or about September 5, 2025. This proxy statement/prospectus is not intended to be and is not a prospectus for purposes of the Israeli Securities Law, 5728 -1968, or Israeli Securities Law, and the Israel Securities Authority, or the ISA, has not approved this proxy statement/prospectus. NLS has supplied all information contained or incorporated by reference into this proxy statement/prospectus relating to NLS, and Kadimastem has supplied all information contained or incorporated by reference into this proxy statement/prospectus relating to Kadimastem. NLS and Kadimastem have both contributed to the information related to the Merger contained in this proxy statement/prospectus. You are cautioned not to rely on any information other than the information contained in or incorporated by reference into this proxy statement/prospectus. No one has been authorized to provide you with information that is different from that contained in or incorporated by reference into this proxy statement/prospectus. This proxy statement/prospectus is dated September 3, 2025. You should not assume that the information contained in this proxy statement/prospectus is accurate as of any other date, nor should you assume that the information incorporated by reference into this proxy statement/prospectus is accurate as of any date other than the date of such incorporated document. The mailing of this proxy statement/prospectus to our shareholders will not create any implication to the contrary. This proxy statement/prospectus does not constitute an offer to sell, or a solic